Held by 2 specialist biotech funds
# Signal Note: Eventide Initiates KVUE Position Eventide's entry into Kenvue—a $4.3B consumer health spinoff from J&J (2023)—signals conviction in OTC portfolio stabilization and potential M&A optionality in the fragmented consumer wellness space. The position timing coincides with KVUE's operational normalization post-spin and potential activist interest, though the company lacks pipeline catalysts typical of Eventide's biotech focus, suggesting this reflects portfolio diversification rather than clinical innovation.